Caribou's Q2 Loss Narrows to $24.3M; ATM Sales Add $18.3M While Cash Runway Holds at 12 Months
CRBU sits 17% above its 52-week low of $1.38.
Summary
Caribou Biosciences reported a narrower Q2 net loss of $24.3M and raised $18.3M via ATM sales, maintaining a 12-month cash runway.
Key Events · Earnings and Guidance · CRBU
-
Q2 Net Loss Narrows
Net loss for Q2 2026 came in at $24.3M, down from $54.1M in Q2 2025, driven by lower R&D and G&A expenses following the 2025 restructuring.
-
ATM Sales Add $18.3M
During Q2 2026, 9,006,276 shares were sold at an average price of $2.03 per share for gross proceeds of $18.3M; $75.2M remains available under the ATM program.
-
Cash Runway Maintained
Cash, cash equivalents, and marketable securities totaled $113.8M as of June 30, 2026, sufficient to fund operations for at least 12 months.
-
Share Count Increases
Shares outstanding rose to 105,995,653 as of June 30, 2026, from 95,143,690 at year-end 2025, reflecting ATM sales and equity compensation.
Analysis · CRBU · Life Sciences
The Q2 2026 10-Q reveals a net loss of $24.3 million, down from $54.1 million a year earlier, as lower R&D and G&A spending following last year's restructuring took hold. During the quarter, the company raised $18.3 million in gross proceeds through its at-the-market facility, selling 9.0 million shares at an average price of $2.03—a meaningful dilution for existing holders but one that keeps the cash runway at 12 months. With $113.8 million in cash and marketable securities, operations can be funded into mid-2027, though the ATM overhang remains: $75.2 million is still available for sale under the program.
At the time of this filing, CRBU was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159.7M. The 52-week trading range was $1.38 to $3.54. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.